| Prescribing in type 2 diabetes patients with and without cardiovascular disease history: a descriptive analysis in the UK CPRD RE Farmer, I Beard, SI Raza, ND Gollop, N Patel, A Tebboth, ... Clinical Therapeutics 43 (2), 320-335, 2021 | 33 | 2021 |
| Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK M Ramos, MH Cummings, A Ustyugova, SI Raza, SU de Silva, M Lamotte Diabetes Therapy 11, 2041-2055, 2020 | 25 | 2020 |
| Differential Appraisal of Functional Outcome Measures by Health Technology Assessment (HTA) Agencies When Reviewing Therapies for Rare Muscular, Skeletal and Neurodegenerative … S Raza, I Keyzor, S Shohet, M Zalewska, N Hummel, M Brougham Value in Health 25 (1), S175, 2022 | 2 | 2022 |
| Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom KG Lena Hubig, Anna-Katrine Sussex, Alasdair MacCulloch, Derralynn Hughes ... Journal of Health Economics and Outcome Research 10 (1), 2023 | 1 | 2023 |
| Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data S Fu, N Hummel, T Mozaffar, J Castelli, B Fox, I Keyzor, S Raza, ... World Muscle Society Annual Congress 12, 2022 | 1 | 2022 |
| Association of Walking Distance with Quality of Life and Other Patient-Reported Outcomes in Pompe Disease S Raza, I Keyzor, S Shohet, A Chandak, A Cheng, N Hummel Value in Health 25 (7), S553, 2022 | 1 | 2022 |
| Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease KG Claeys, H Kushlaf, S Raza, N Hummel, S Shohet, I Keyzor, A Kopiec, ... Orphanet Journal of Rare Diseases 19 (1), 154, 2024 | | 2024 |
| Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS®) physical function questionnaire in late-onset Pompe disease using … PS Kishnani, S Shohet, S Raza, N Hummel, JP Castelli, S Sitaraman Das, ... Journal of Patient-Reported Outcomes 8 (1), 13, 2024 | | 2024 |
| HTA103 Systematic Literature Reviews to Identify Clinical and Economic Outcomes in Adults With Pompe Disease S Raza, I Keyzor, S Clarke, G McCaughey, F Bolan, J Kaut, L Ashworth, ... Value in Health 26 (12), S338, 2023 | | 2023 |
| EE401 A Comparison of Health State Occupancy Between Cipaglucosidase Alfa/Miglustat and Alglucosidase Alfa Within a Cost-Effectiveness Modelling Analysis of Late-Onset Pompe … S Raza, A Dymond, W Green, R Graham, I Keyzor, N Johnson, ... Value in Health 26 (12), S128, 2023 | | 2023 |
| P373 Effect size analysis of cipaglucosidase alfa+ miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL J Diaz-Manera, D Bratkovic, B Byrne, K Claeys, M Dimachkie, H Kushlaf, ... Neuromuscular Disorders 33, S151, 2023 | | 2023 |
| P371 Switching treatment to cipaglucosidase alfa+ miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease K Claeys, B Byrne, J Diaz-Manera, M Dimachkie, P Kishnani, H Kushlaf, ... Neuromuscular Disorders 33, S151, 2023 | | 2023 |
| The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi MM Chikumbanje, S Raza, L Barham Value in Health Regional Issues 37, 53-61, 2023 | | 2023 |
| Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: A network meta-analysis with patient-level and aggregate data J Castelli, S Fu, N Hummel, T Mozaffar, B Fox, I Keyzor, S Raza, ... Molecular Genetics and Metabolism 138 (2), 107046, 2023 | | 2023 |
| Quality of life with late-onset Pompe disease: Qualitative interviews and general public utility estimation A MacCulloch, L Hubig, D Hughes, R Graham, AK Sussex, L Morris, ... Molecular Genetics and Metabolism 138 (2), 107219, 2023 | | 2023 |
| European Market Access Landscape Analysis Of Reimbursement Drivers In Pompe Disease: Results From 26 Payer Interviews A MacCulloch, S Raza, S Shohet, N Schammel, P Net International Journal of Technology Assessment in Health Care 38 (S1), S84-S84, 2022 | | 2022 |
| Improving the Methods of Vignette Development for Utility Estimation: A Case Study in Pompe Disease H de Freitas, R Graham, L Hubig, AK Sussex, S Raza, A MacCulloch, ... Value in Health 25 (12), S408, 2022 | | 2022 |
| Indirect treatment comparison of three enzyme replacement treatments for late-onset Pompe disease: a network meta-analysis with patient-level and aggregate data World Muscle Society 2022, https://ir.amicusrx.com/static-files/fc4, 2022 | | 2022 |
| European Market Access Landscape Analysis of Reimbursement Drivers in Pompe Disease: Results from 26 Payer Interviews PN Alasdair MacCulloch, Syed Raza, Simon Shohet, Nico Schamell HTAi, 2022 | | 2022 |
| P246: Characteristics associated with choice of glucose lowering drug class at time of initiation: An exploratory analysis in the UK clinical practice research datalink RE Farmer, I Beard, AP McGovern, A Tebboth, ND Gollop, SI Raza, ... Diabetic Medicine 38 (S1), e47_14556, 2021 | | 2021 |
Andrew Peter McGovernMedical Doctor, University of Exeter在 mcgov.co.uk 的电子邮件经过验证
